AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Supernus Pharmaceuticals ... (SUPN)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

34.52

1.00 (2.98%)

At close: Feb 20, 2025, 3:59 PM

34.99

1.35%

After-hours: Feb 20, 2025, 05:13 PM EST

undefined% (undefined)

Bid	33.7
Market Cap	1.91B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	1.07
PE Ratio (ttm)	32.27
Forward PE	n/a
Analyst	Hold

Ask	35.48
Volume	420,800
Avg. Volume (20D)	385,737
Open	33.54
Previous Close	33.52
Day's Range	33.49 - 34.52
52-Week Range	25.53 - 40.28
Beta	undefined

About SUPN

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy tr...

[Show more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

IPO Date May 1, 2012

Employees 652

Stock Exchange NASDAQ

Ticker Symbol SUPN

Website https://www.supernus.com

Full Company Profile

Analyst Forecast

According to 2 analyst ratings, the average rating for SUPN stock is "Hold." The 12-month stock price forecast is $36, which is an increase of 4.27% from the latest price.

Buy 0.00%

Hold 100.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Supernus Pharmaceuticals Inc. is scheduled to release its earnings on Feb 25, 2025, after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 days ago New

-15.67%

Supernus Pharmaceuticals shares are trading lower ... Unlock content with Pro Subscription

3 days ago

+1.64%

Supernus Pharmaceuticals shares are trading lower after the company announced that the Phase 2b study of SPN-820 in adults with treatment-resistant depression did not demonstrate a statistically significant improvement on the primary endpoint of change from baseline in the Montgomery-Åsberg Depression Rating Scale.

News

2 days ago · accessnewswire.com

SUPN ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Supernus Pharmaceuticals, Inc.

NEW YORK, NY / ACCESS Newswire / February 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NA...

2 days ago · benzinga.com

Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial

On Tuesday, Supernus Pharmaceuticals, Inc. SUPN revealed the topline data from the Phase 2b study of SPN-820 in adults with treatment-resistant depression (TRD).

2 weeks ago · zacks.com

Supernus (SUPN) Moves to Strong Buy: Rationale Behind the Upgrade

Supernus (SUPN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).